Drug–gene interaction studies highlight antipsychotics, estrogen-related drugs, DRD2-targeting drugs, calcium channel modulators, and serotonin receptor antagonism as potential drugs to counteract transcriptional effects of depression risk [3, 162]. Here, DRD2 is linked to depressive symptom measurement.